1.Knowledge, Attitudes and Sources of Information on Breastfeeding among Pregnant Mothers
Ay Eeng Tan ; Wai Kwong Choong ; Pooi Yan Leong ; Wei Mui Ng ; Soon Leong Yong
Medicine and Health 2008;3(1):30-37
This is a cross-sectional study on 218 pregnant mothers in an urban government Hospital.
The study aimed to assess knowledge, attitudes and sources of information on
breastfeeding. The results could be utilised to promote breastfeeding. Almost all the
respondents (96.8%) intended to breastfeed their newborns. Most of them (74.8%) were
knowledgeable about breastfeeding i.e. colostrum and breast milk was the best food, good
for resistance against disease and allergy, filling up stomach easily, helpful in teeth
development and maternal recovery after birth, increased bonding, was easy and
economical. The two main misconceptions were mothers would stop breastfeeding when
infant or mother was sick, and giving clear fluid to the exclusively breastfed infants to
prevent dehydration. Most mothers (83.9%) responded positively towards breastfeeding i.e. it was easier than infant formula, had no negative effect on marital relationship or
family care, would commence breastfeeding straight after delivery, agreeable to the
banning of bottles and teats in hospital and they would not stop breastfeeding even if
husband discouraged them. Only 56.9% of the mothers believed they could breastfeed
their babies with modesty anywhere. The main sources of information were attained from
the mass media (34.9%), antenatal class (32.1%) and other mothers with breastfeeding experiences.
2.Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
Wei LÜ ; Hai-Hong YANG ; Yun-Ming FAN ; Takming LI ; Li-Fan ZHANG ; Chongseong MUI ; Hong-Wei FAN ; Bao-Tong ZHOU ; Zheng-Yin LIU ; Hou NG ; Xiao-Qing LIU
Chinese Medical Journal 2013;126(12):2333-2336
BACKGROUNDTelbivudine, one of the five nucleos(t)ide antiviral drugs, was reported to be superior to lamivudine in a better biochemical, virological, and histological response for treatment-naive patients in the GLOBE trial. The aim of this study was to determine the antiviral potency, viral resistance, and the signifcance of early response for long-term telbivudine treatment.
METHODSWe recruited 161 patients of chronic hepatitis B (CHB) on telbivudine between January 2009 and September 2011 in Macau, China. The serum hepatitis B virus DNA levels, hepatitis B e antigen (HBeAg) seroconversion, alanine aminotransferase (ALT) normalization, and viral resistance were analyzed.
RESULTSThe median age and follow-up duration were 48 years and 16.9 months. All patients were followed up for at least 6 months, while data were collected for 132, 120, 95, and 53 patients at 12, 24, 48, and 96 weeks respectively. The cumulative HBeAg seroconversion rate was 20.8% and only three patients (1.9%) presented with telbivudine low level resistance. The ALT normalization rates were 76.9% at 48 weeks and 77.6% at 96 weeks. Undetectable HBV DNA was achieved by 1.8%, 31.6%, 60%, and 74.1% in HBeAg positive patients and 29.3%, 60.3%, 84%, and 84.6% in HBeAg negative patients at each time point. Week 12 HBV DNA level < 1000 copies/ml (< 200 IU/ml) was a better predictor of viral suppression at 2-year follow-up (P = 0.001, OR = 27.00) than undetectable HBV DNA level at week 24 (P = 0.120, OR = 4.81).
CONCLUSIONSTwo-year telbivudine treatment yielded high rates of viral suppression and ALT normalization. Serum HBV DNA level at week 12 is a superior predictor for long-term viral suppression.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Alanine Transaminase ; blood ; Antiviral Agents ; therapeutic use ; DNA, Viral ; blood ; Drug Resistance, Viral ; Female ; Hepatitis B, Chronic ; drug therapy ; virology ; Humans ; Male ; Middle Aged ; Thymidine ; analogs & derivatives ; therapeutic use ; Time Factors
3.Pre- and apnoeic high-flow oxygenation for rapid sequence intubation in the emergency department (the Pre-AeRATE trial): A multicentre randomised controlled trial.
Mui Teng CHUA ; Wei Ming NG ; Qingshu LU ; Matthew Jian Wen LOW ; Amila PUNYADASA ; Matthew Edward COVE ; Ying Wei YAU ; Faheem Ahmed KHAN ; Win Sen KUAN
Annals of the Academy of Medicine, Singapore 2022;51(3):149-160
INTRODUCTION:
Evidence regarding the efficacy of high-flow nasal cannula (HFNC) oxygenation for preoxygenation and apnoeic oxygenation is conflicting. Our objective is to evaluate whether HFNC oxygenation for preoxygenation and apnoeic oxygenation maintains higher oxygen saturation (SpO2) during rapid sequence intubation (RSI) in ED patients compared to usual care.
METHODS:
This was a multicentre, open-label, randomised controlled trial in adult ED patients requiring RSI. Patients were randomly assigned 1:1 to either intervention (HFNC oxygenation at 60L/min) group or control (non-rebreather mask for preoxygenation and nasal prongs of at least 15L/min oxygen flow for apnoeic oxygenation) group. Primary outcome was lowest SpO2 during the first intubation attempt. Secondary outcomes included incidence of SpO2 falling below 90% and safe apnoea time.
RESULTS:
One hundred and ninety patients were included, with 97 in the intervention and 93 in the control group. Median lowest SpO2 during the first intubation attempt was 100% in both groups. Incidence of SpO2 falling below 90% was lower in the intervention group (15.5%) compared to the control group (22.6%) (adjusted relative risk=0.68, 95% confidence interval [CI] 0.37-1.25). Post hoc quantile regression analysis showed that the first quartile of lowest SpO2 during the first intubation attempt was greater by 5.46% (95% CI 1.48-9.45%, P=0.007) in the intervention group.
CONCLUSION
Use of HFNC for preoxygenation and apnoeic oxygenation, when compared to usual care, did not improve lowest SpO2 during the first intubation attempt but may prolong safe apnoea time.
Adult
;
Cannula
;
Emergency Service, Hospital
;
Humans
;
Intubation, Intratracheal
;
Rapid Sequence Induction and Intubation
;
Respiration, Artificial